These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 39047224)
21. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176 [TBL] [Abstract][Full Text] [Related]
22. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report. Ren KH; Qin WW; Wang Y; Peng JC; Hu WX Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses. Zhao B; Wang Y; Wang Y; Chen W; Zhou L; Liu PH; Kong Z; Dai C; Wang Y; Ma W Aging (Albany NY); 2020 Jul; 12(14):14244-14270. PubMed ID: 32669477 [TBL] [Abstract][Full Text] [Related]
24. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598 [TBL] [Abstract][Full Text] [Related]
25. Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer. Jia F; Cheng X; Zeng H; Miao J; Hou M J BUON; 2019; 24(2):578-584. PubMed ID: 31128009 [TBL] [Abstract][Full Text] [Related]
26. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy? Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000 [TBL] [Abstract][Full Text] [Related]
27. Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer. Tozuka T; Noro R; Mizutani H; Kurimoto F; Hakozaki T; Hisakane K; Naito T; Takahashi S; Taniuchi N; Yajima C; Hosomi Y; Hirose T; Minegishi Y; Okano T; Kamio K; Yamaguchi T; Seike M; Lung Cancer; 2024 May; 191():107540. PubMed ID: 38614069 [TBL] [Abstract][Full Text] [Related]
28. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931 [TBL] [Abstract][Full Text] [Related]
29. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711 [TBL] [Abstract][Full Text] [Related]
30. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study. Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430 [TBL] [Abstract][Full Text] [Related]
31. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy. Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126 [TBL] [Abstract][Full Text] [Related]
32. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. Cai L; Zhu JF; Zhang XW; Lin SX; Su XD; Lin P; Chen K; Zhang LJ J Neurooncol; 2014 Nov; 120(2):423-30. PubMed ID: 25098700 [TBL] [Abstract][Full Text] [Related]
33. Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer. El Shafie RA; Seidensaal K; Bozorgmehr F; Kazdal D; Eichkorn T; Elshiaty M; Weber D; Allgäuer M; König L; Lang K; Forster T; Arians N; Rieken S; Heussel CP; Herth FJ; Thomas M; Stenzinger A; Debus J; Christopoulos P ESMO Open; 2021 Jun; 6(3):100161. PubMed ID: 34090172 [TBL] [Abstract][Full Text] [Related]
34. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. Yu X; Sheng J; Pan G; Fan Y Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485 [TBL] [Abstract][Full Text] [Related]
35. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis. Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302 [TBL] [Abstract][Full Text] [Related]
36. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis. Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study. Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626 [TBL] [Abstract][Full Text] [Related]
38. Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer. Bauman JR; Liu G; Preeshagul I; Liu SV; Melosky B; Abrahami D; Li B; Thomaidou D; Duncan K; Krulewicz S; Rupp M; Lin JJ Lung Cancer; 2024 Sep; 195():107919. PubMed ID: 39197358 [TBL] [Abstract][Full Text] [Related]
39. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer. Chang GC; Shih JY; Yu CJ; Chao HS; Yang CT; Lin CC; Hung JY; Hsiao SY; Wang CC; Chian CF; Hsia TC; Chen YM PLoS One; 2024; 19(5):e0303046. PubMed ID: 38753697 [TBL] [Abstract][Full Text] [Related]
40. Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration. Robledo KP; Lefresne S; Soon YY; Sahgal A; Pinkham MB; Nichol A; Soo RA; Parmar A; Hegi-Johnson F; Doherty M; Solomon BJ; Shultz DB; Tham IW; Sacher AG; Tey J; Leong CN; Koh WY; Huang Y; Ang YLE; Low J; Yong C; Lim MC; Tan AP; Lee CK; Ho C BMJ Open; 2024 Jul; 14(7):e078335. PubMed ID: 38969367 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]